Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inositol nicotinate
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Inositol nicotinate is a compound formed from niacin (vitamin B3) and inositol. It is used primarily as a vasodilator and lipid-lowering agent. The drug acts as a source of niacin when hydrolyzed in the body and is associated with reduced flushing compared to other forms of niacin due to its slower breakdown. Its main mechanisms include widening blood vessels (vasodilation), lowering blood levels of fats such as cholesterol and triglycerides by acting on hydroxycarboxylic acid receptor 2 (HCAR2/GPR109A) and hydroxycarboxylic acid receptor 3 (HCAR3/GPR109B), decreasing lipolysis via cAMP reduction in adipocytes. In clinical practice—especially Europe—it has been prescribed for peripheral vascular diseases such as intermittent claudication and Raynaud’s phenomenon. Other uses include high cholesterol management and improving symptoms related to poor circulation[1][2][3][5].
- Brand names
- HexopalNiacin NFHexolipErgovasInohexEcasXantirinGrinotelCalmigen ForteHrb PlusBipoxim
- Other names
- no-flush niacinmeso-inositol hexanicotinate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)HCAR3 (Hydroxycarboxylic acid receptor 3)
Beyond the preview
Go deeper on inositol nicotinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inositol nicotinate.